fangchinoline has been researched along with Multiple Myeloma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Ha, IJ; Jung, YY; Sethi, G; Um, JY | 1 |
| Ahn, KS; Alharbi, SA; Chinnathambi, A; Jung, YY; Sethi, G; Shair, OHM; Shanmugam, MK; Um, JY | 1 |
2 other study(ies) available for fangchinoline and Multiple Myeloma
| Article | Year |
|---|---|
Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model.
Topics: Animals; Benzylisoquinolines; Mice; Multiple Myeloma; Oxidative Stress; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2022 |
Fangchinoline, a Bisbenzylisoquinoline Alkaloid can Modulate Cytokine-Impelled Apoptosis via the Dual Regulation of NF-κB and AP-1 Pathways.
Topics: Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; I-kappa B Kinase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; NF-kappa B; Phosphorylation; Signal Transduction; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2019 |